Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Update

Key Points

• Lyell Immunopharma saw a significant increase of 43.4% in short interest in September, totaling 233,100 shares shorted, which represents 2.7% of the company's total shares.
• Institutional investors now own 66.05% of Lyell Immunopharma, with notable increases from Almitas Capital and Acadian Asset Management during the 1st quarter.
• Analysts have mixed ratings on the stock, with a consensus rating of "Sell" and a price target of $15.00, despite one upgrade to "Hold" by Wall Street Zen earlier in September.

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) was the target of a significant increase in short interest during the month of September. As of September 30th, there was short interest totaling 233,100 shares, an increase of 43.4% from the September 15th total of 162,600 shares. Currently, 2.7% of the company's shares are sold short. Based on an average trading volume of 53,000 shares, the short-interest ratio is presently 4.4 days. Based on an average trading volume of 53,000 shares, the short-interest ratio is presently 4.4 days. Currently, 2.7% of the company's shares are sold short.

Hedge Funds Weigh In On Lyell Immunopharma

A number of large investors have recently modified their holdings of LYEL. Almitas Capital LLC increased its stake in Lyell Immunopharma by 136.3% during the 1st quarter. Almitas Capital LLC now owns 2,482,606 shares of the company's stock valued at $1,336,000 after purchasing an additional 1,432,086 shares in the last quarter. Nuveen LLC bought a new position in Lyell Immunopharma during the first quarter valued at about $345,000. Orbimed Advisors LLC bought a new stake in Lyell Immunopharma in the second quarter worth about $457,000. Acadian Asset Management LLC grew its holdings in Lyell Immunopharma by 204.2% during the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company's stock valued at $354,000 after buying an additional 443,614 shares in the last quarter. Finally, Walleye Capital LLC bought a new position in shares of Lyell Immunopharma in the second quarter valued at approximately $258,000. 66.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

LYEL has been the subject of several research analyst reports. Wall Street Zen upgraded Lyell Immunopharma from a "sell" rating to a "hold" rating in a research note on Monday, September 1st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Lyell Immunopharma in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Sell" and a consensus price target of $15.00.

Lyell Immunopharma Trading Up 2.1%

LYEL traded up $0.36 during trading on Thursday, reaching $17.39. 6,227 shares of the company's stock were exchanged, compared to its average volume of 75,114. Lyell Immunopharma has a one year low of $7.65 and a one year high of $30.00. The firm has a fifty day moving average price of $13.82 and a two-hundred day moving average price of $11.01. The stock has a market capitalization of $333.97 million, a PE ratio of -0.72 and a beta of -0.07.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($2.89) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.80) by $0.91. Lyell Immunopharma had a negative net margin of 552,328.31% and a negative return on equity of 85.58%. The company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.00 million. Sell-side analysts expect that Lyell Immunopharma will post -0.78 earnings per share for the current year.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.